WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW), a manufacturer of artificial heart valves, Monday said it received U.S. Food and Drug Administration, or FDA, clearance for its noninvasive monitoring system ClearSight system that provides blood volume and blood flow information for patients who are at risk of post-surgical complications
The ClearSight system comprises of a finger cuff that provides up-to-the-minute information, and software elements that have been used for the noninvasive monitoring of the blood pressure of astronauts in space, according to the company.
'Proper intraoperative management of moderate and high-risk surgery patients is critical to help reduce the risk of post-surgical complications,' said Julie Thacker, surgical oncologist at Duke University Hospital.
Copyright RTT News/dpa-AFX